Collegium Pharmaceutical (COLL)
(Delayed Data from NSDQ)
$31.78 USD
0.00 (0.00%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $31.80 +0.02 (0.06%) 6:56 PM ET
4-Sell of 5 4
A Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$31.78 USD
0.00 (0.00%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $31.80 +0.02 (0.06%) 6:56 PM ET
4-Sell of 5 4
A Value B Growth A Momentum A VGM
Zacks News
Strength Seen in Collegium Pharmaceutical (COLL): Can Its 8.4% Jump Turn into More Strength?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q3 Earnings
by Zacks Equity Research
While the top- and bottom-line numbers for Collegium Pharmaceutical (COLL) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Catalyst (CPRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Exscientia PLC Sponsored ADR (EXAI) Stock Jumps 13.5%: Will It Continue to Soar?
by Zacks Equity Research
Exscientia PLC Sponsored ADR (EXAI) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Is Collegium Pharmaceutical (COLL) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's What Key Metrics Tell Us About Collegium Pharmaceutical (COLL) Q2 Earnings
by Zacks Equity Research
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) Q2 Earnings Beat Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 3.28% and 1.76%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Will US Business Strength Aid Acadia's (ACHC) Q2 Earnings?
by Zacks Equity Research
Strength in US operations, stemming from higher patient days and revenue per patient day, is expected to have aided Acadia Healthcare's (ACHC) Q2 performance. Rising expenses are likely to have partially offset the same.
Do Options Traders Know Something About Collegium Pharmaceutical (COLL) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Collegium Pharmaceutical (COLL) stock based on the movements in the options market lately.
Collegium Pharmaceutical (COLL) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended March 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) Q1 Earnings Meet Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 0% and 4.07%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Pacira (PCRX) Lags Q1 Earnings Estimates
by Zacks Equity Research
Pacira (PCRX) delivered earnings and revenue surprises of -11.67% and 2.12%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
COLL vs. ZTS: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
Pacira's (PCRX) Q4 Earnings Match Estimates, Revenues Fall
by Zacks Equity Research
Pacira BioSciences (PCRX) reports mixed fourth-quarter financial results, where earnings match estimates, but revenues miss the mark.
Collegium Pharmaceutical (COLL) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 5.83% and 2%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Apellis' (APLS) Earnings Top, Empaveli Sales Boost Revenues
by Zacks Equity Research
Apellis Pharmaceuticals (APLS) reports better-than-expected results, beating both earnings and revenue estimates. Empaveli sales continue to boost product revenues for the company.
Esperion (ESPR) Q4 Loss Narrows, Revenues Miss, Stock Down
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports mixed fourth-quarter results, beating earnings estimates but missing the same on sales.
Will Cronos Group (CRON) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Cronos (CRON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
COLL or ZTS: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
COLL vs. ZTS: Which Stock Is the Better Value Option?
MEI Pharma, Inc. (MEIP) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
MEI Pharma, Inc. (MEIP) delivered earnings and revenue surprises of 150% and 237.82%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Find 'Strong Buy' Stocks Near their Highs for February
by Benjamin Rains
Let's explore a Zacks screen that helps investors find 'Strong Buy' stocks trading near their highs as we head into February...
Zacks.com featured highlights MercadoLibre, Axcelis Technologies, Shinhan Financial, Pinduoduo and Collegium Pharmaceutical
by Zacks Equity Research
MercadoLibre, Axcelis Technologies, Shinhan Financial, Pinduoduo and Collegium Pharmaceutical have been highlighted in this Screen of The Week article.